These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38692883)

  • 1. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
    Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
    Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
    Johannesson M; Söderberg L; Zachrisson O; Fritz N; Kylefjord H; Gkanatsiou E; Button E; Svensson AS; Rachalski A; Nygren P; Osswald G; Lannfelt L; Möller C
    Mol Cell Neurosci; 2024 Sep; 130():103949. PubMed ID: 38906341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
    McDade E; Cummings JL; Dhadda S; Swanson CJ; Reyderman L; Kanekiyo M; Koyama A; Irizarry M; Kramer LD; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):191. PubMed ID: 36544184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease.
    Park J; Simpson C; Patel K
    Ann Pharmacother; 2024 Oct; 58(10):1045-1053. PubMed ID: 38095619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.
    Hossain MF; Husna AU; Kharel M
    Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.
    Lannfelt L
    Ups J Med Sci; 2023; 128():. PubMed ID: 38084203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Abdelazim K; Allam AA; Afifi B; Abdulazeem H; Elbehiry AI
    Neurol Sci; 2024 Aug; 45(8):3583-3597. PubMed ID: 38565747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.
    Yoon CH; Groff C; Criss O
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
    Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD
    J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.
    Kurkinen M
    Adv Clin Exp Med; 2023 Sep; 32(9):943-947. PubMed ID: 37676096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lecanemab: First Approval.
    Hoy SM
    Drugs; 2023 Mar; 83(4):359-365. PubMed ID: 36856953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta.
    Rofo F; Buijs J; Falk R; Honek K; Lannfelt L; Lilja AM; Metzendorf NG; Gustavsson T; Sehlin D; Söderberg L; Hultqvist G
    Transl Neurodegener; 2021 Sep; 10(1):38. PubMed ID: 34579778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.